Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 38.8% in January

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a large drop in short interest in January. As of January 15th, there was short interest totalling 93,300 shares, a drop of 38.8% from the December 31st total of 152,400 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average trading volume of 111,600 shares, the short-interest ratio is currently 0.8 days.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $1.99 on Wednesday. The business has a fifty day simple moving average of $1.92 and a 200 day simple moving average of $2.97. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.